Charles Schwab
SABS icon

Charles Schwab’s SAB Biotherapeutics SABS Stock Holding History

Charles Schwab’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Buy
+105,682
New +$393K ﹤0.01% 3271
2024
Q1 		– Sell
-1,624
Closed -$11.2K – 3510
2023
Q4 		$11.2K Hold
1,624
– – ﹤0.01% 3521
2023
Q3 		$10.2K Hold
1,624
– – ﹤0.01% 3563
2023
Q2 		$13.5K Hold
1,624
– – ﹤0.01% 3588
2023
Q1 		$7.14K Hold
1,624
– – ﹤0.01% 3544
2022
Q4 		$9.58K Hold
1,624
– – ﹤0.01% 3533
2022
Q3 		$12K Hold
1,624
– – ﹤0.01% 3504
2022
Q2 		$24K Buy
+1,624
New +$34.1K ﹤0.01% 3509
2022
Q1 		– Sell
-1,000
Closed -$79K – 3614
2021
Q4 		$79K Buy
+1,000
New +$93.8K ﹤0.01% 3467

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's SABS Position: Q2 2026 in Review

Charles Schwab opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 105,682 shares worth $412K. The stake represents ﹤0.01% of the portfolio and ranks #3271 among its holdings. This is a return to the name: Charles Schwab previously reported a position in SABS as recently as Q4 2023.

Charles Schwab first reported a position in SABS in Q4 2021 and has held it in 9 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Charles Schwab held 105,682 shares of SAB Biotherapeutics worth $412K as of Q2 2026.
  • SAB Biotherapeutics was a new Charles Schwab position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3271 holding.
  • Charles Schwab first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.